2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy

Nature Communications

Volumn 5, Issue , 2014, Pages

  Li, Jingmei ^a,b   Lindström, Linda S ^c,d   Foo, Jia N ^a   Rafiq, Sajjad ^e   Schmidt, Marjanka K ^f   Pharoah, Paul D P ^g   Michailidou, Kyriaki ^g   Dennis, Joe ^g   Bolla, Manjeet K ^g   Wang, Qin ^g   Van'T Veer, Laura J ^f   Cornelissen, Sten ^f   Rutgers, Emiel ^f   Southey, Melissa C ^h   Apicella, Carmel ⁱ   Dite, Gillian S ⁱ   Hopper, John L ^i,j   Fasching, Peter A ^k,l   Haeberle, Lothar ^k   Ekici, Arif B ^m   Beckmann, Matthias W ^k   Blomqvist, Carl ⁿ   Muranen, Taru A ⁿ   Aittomäki, Kristiina ⁿ   Lindblom, Annika ^d   Margolin, Sara ^d   Mannermaa, Arto ^o,p   Kosma, Veli Matti ^o,p   Hartikainen, Jaana M ^o,p   Kataja, Vesa ^o,p,q   Chenevix Trench, Georgia ^r   Investigators, Kconfab ^s   Phillips, Kelly Anne ^h,i   McLachlan, Sue Anne ^t   Lambrechts, Diether ^u,v   Thienpont, Bernard ^u,v   Smeets, Ann ^w   Wildiers, Hans ^w   Chang Claude, Jenny ^x   Flesch Janys, Dieter ^x,y   Seibold, Petra ^x   Rudolph, Anja ^x   Giles, Graham G ^i,z   Baglietto, Laura ^i,z   Severi, Gianluca ^i,z   Haiman, Christopher A ^aa   Henderson, Brian E ^ab   Schumacher, Fredrick ^aa   Le Marchand, Loic ^ab   Kristensen, Vessela ^ac,ad,ae   Alnæs, Grethe I Grenaker ^ac,ad   Borresen Dale, Anne Lise ^ac,ad   Nord, Silje ^ac,ad   Winqvist, Robert ^af   Pylkäs, Katri ^af   Jukkola Vuorinen, Arja ^ag   Grip, Mervi ^ag   Andrulis, Irene L ^ah,ai   Knight, Julia A ^ah,aj   Glendon, Gord ^ah   Tchatchou, Sandrine ^ah   Devilee, Peter ^ak   Tollenaar, Robert ^ak   Seynaeve, Caroline ^al   Hooning, Maartje ^al   Kriege, Mieke ^al   Hollestelle, Antoinette ^al   Van Den Ouweland, Ans ^am   Li, Yi ^a   Hamann, Ute ^x   Torres, Diana ^x,an   Ulmer, Hans U ^ao   Rüdiger, Thomas ^ap   Shen, Chen Yang ^aq,ar   Hsiung, Chia Ni ^aq   Wu, Pei Ei ^as   Chen, Shou Tung ^at   Teo, Soo Hwang ^au,av   Taib, Nur Aishah Mohd ^av   Har Yip, Cheng ^av   Fuang Ho, Gwo ^av   Matsuo, Keitaro ^aw   Ito, Hidemi ^ax   Iwata, Hiroji ^ax   Tajima, Kazuo ^ax   Kang, Daehee ^j,ay   Choi, Ji Yeob ^j   Park, Sue K ^j,ay   Yoo, Keun Young ^j   Maishman, Tom ^e   Tapper, William J ^e   Dunning, Alison ^g   Shah, Mitul ^g   Luben, Robert ^g   Brown, Judith ^g   Chuen Khor, Chiea ^a   Eccles, Diana M ^e   Nevanlinna, Heli ⁿ   Easton, Douglas ^g   Humphreys, Keith ^d   Liu, Jianjun ^a   Hall, Per ^d   Czene, Kamila ^d   more..

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j Seoul National University   (South Korea)

^k UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁿ UNIVERSITY OF HELSINKI   (Finland)

^o UNIVERSITY OF EASTERN FINLAND   (Finland)

^p KUOPIO UNIVERSITY HOSPITAL   (Finland)

^q JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^r QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^s PETER MACCALLUM CANCER CENTRE   (Australia)

^t ST VINCENT S HOSPITAL   (Australia)

^u DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^v UNIVERSITY OF LEUVEN   (Belgium)

^w UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^x GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^y UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^z CANCER EPIDEMIOLOGY CENTRE   (Australia)

^aa UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^ab UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^ac OSLO UNIVERSITY HOSPITAL   (Norway)

^ad UNIVERSITY OF OSLO   (Norway)

^ae AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^af UNIVERSITY OF OULU   (Finland)

^ag OULU UNIVERSITY HOSPITAL   (Finland)

^ah MOUNT SINAI HOSPITAL   (Canada)

^ai UNIVERSITY OF TORONTO   (Canada)

^aj UNIVERSITY OF TORONTO   (Canada)

^ak LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^al ERASMUS MC CANCER INSTITUTE   (Netherlands)

^am ERASMUS MEDICAL CENTER   (Netherlands)

^an PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^ao Frauenklinik der Stadtklinik Baden Baden   (Germany)

^ap STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^aq INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^ar CHINA MEDICAL UNIVERSITY   (Taiwan)

^as ACADEMIA SINICA   (Taiwan)

^at CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^au CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^av UNIVERSITY OF MALAYA   (Malaysia)

^aw KYUSHU UNIVERSITY   (Japan)

^ax AICHI CANCER CENTER HOSPITAL   (Japan)

^ay Seoul National University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; GENETIC MARKER;

CANCER; CHEMOTHERAPY; ESTROGENIC COMPOUND; GENETIC ANALYSIS; HERITABILITY; PUBLIC HEALTH; SURVIVAL; WOMENS HEALTH;

ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSE OF DEATH; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; CAUCASIAN; CHROMOSOME 2; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC MARKER; GENETICS; KAPLAN MEIER METHOD; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

EUROPE;

BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 2; DRUG THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC MARKERS; HUMANS; KAPLAN-MEIER ESTIMATE; LINKAGE DISEQUILIBRIUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84902763179     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5051     Document Type: Article

References (33)

1. Lindstrom, L. S. et al. Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol. 8, 1001-1006 (2007). (Pubitemid 47629885)
2. Hartman, M. et al. Is breast cancer prognosis inherited? Breast Cancer Res. 9, R39 (2007).
3. Lindström, L. et al. Association of breast cancer survival among sisters is not explained by shared primary tumour characteristics. Submitted (2013).
4. Verkooijen, H. M. et al. Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics. Int. J. Cancer 130, 2103-2110 (2012).
5. Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12, 68-78 (2012).
6. Honrado, E., Osorio, A., Palacios, J. & Benitez, J. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25, 5837-5845 (2006). (Pubitemid 44453439)
7. Heikkinen, T. et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin. Cancer Res. 15, 3214-3222 (2009).
8. Teo, Z. L. et al. Tumour morphology predicts PALB2 germline mutation status. Br. J. Cancer 109, 154-163 (2013).
9. Stevens, K. N. et al. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res. 71, 6240-6249 (2011).
10. Antoniou, A. C. et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat. Genet. 42, 885-892 (2010).
11. Haiman, C. A. et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat. Genet. 43, 1210-1214 (2011).
12. Broeks, A. et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum. Mol. Genet. 20, 3289-3303 (2011).
13. Stacey, S. N. et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39, 865-869 (2007). (Pubitemid 47014497)
14. Stacey, S. N. et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 40, 703-706 (2008). (Pubitemid 351748861)
15. Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105-113 (2010).
16. Apetoh, L. et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220, 47-59 (2007). (Pubitemid 350045573)
17. Zitvogel, L. & Kroemer, G. The immune response against dying tumor cells: avoid disaster, achieve cure. Cell Death Differ. 15, 1-2 (2008). (Pubitemid 350286166)
18. Michailidou, K. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat. Genet. 45, 353-361 (2013).
19. Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy: BIG 02-98. J. Clin. Oncol. 31, 860-867 (2013).
20. Eccles, D. et al. Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol. BMC Cancer 7, 160 (2007).
21. Copson, E. et al. Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. J. Natl Cancer Inst. 105, 978-988 (2013).
22. Rafiq, S. et al. Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. Cancer Res. 73, 1883-1891 (2013).
23. Huedo-Medina, T. B., Sanchez-Meca, J., Marin-Martinez, F. & Botella, J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol. Methods 11, 193-206 (2006). (Pubitemid 44001277)
24. Schoenfeld, D. Partial residuals for the proportional hazards regression model. Biometrika 69, 239-241 (1982).
25. Nagelkerke, N. J. D. A note on a general definition of the coefficient of determination. Biometrika 78, 691-692 (1991).
26. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559-575 (2007). (Pubitemid 47330214)
27. Milestone in Anhui. Nat. Genet. 43, 613 (2011).
28. Marsigliante, S., Vetrugno, C. & Muscella, A. CCL20 induces migration and proliferation on breast epithelial cells. J. Cell. Physiol. 228, 1873-1883 (2013).
29. Hieshima, K. et al. Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J. Biol. Chem. 272, 5846-5853 (1997). (Pubitemid 27102418)
30. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580-585 (2013).
31. Shu, X. O. et al. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res. 72, 1182-1189 (2012).
32. Kiyotani, K. et al. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum. Mol. Genet. 21, 1665-1672 (2012).
33. Azzato, E. M. et al. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol. Biomarkers Prev. 19, 1140-1143 (2010).